Mediwound Ltd (MDWD) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · United States · ISIN IL0011316309

Price
13.82 USD
Market cap
178.42 m USD
P/E (2025)
–
P/S (2025)
10.52
Dividend yield
0.00 %
Net margin
-140.80 %
Return on equity (ROE)
-54.73 %
Return on assets (ROA)
-27.68 %

Mediwound Ltd financials

Fiscal year20242025
Revenue20.22 m USD16.96 m USD
Gross profit2.63 m USD3.25 m USD
Operating income-19.38 m USD-25.28 m USD
EBIT-29.41 m USD-23.33 m USD
Net income-30.22 m USD-23.88 m USD
Diluted EPS – continuing operations-3.03 USD-2.10 USD

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Mediwound Ltd

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.